Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets

• Published in: MedComm (2020) Vol. 5; no. 10; pp. e761 - n/a
• Main Authors: Jiang, Jun, Han, Donghui, Wang, Jiawei, Wen, Weihong, Zhang, Rui, Qin, Weijun
• Format: Journal Article
• Language: English
• Published: China John Wiley & Sons, Inc 01.10.2024; Wiley
• Subjects: acquired resistance; Cancer; DNA methylation; Kinases; lineage plasticity; Metastasis; neuroendocrine prostate cancer; neuroendocrine transdifferentiation; small cell lung cancer; Tumors; lineage plasticity; neuroendocrine transdifferentiation; small cell lung cancer; neuroendocrine prostate cancer; acquired resistance
• ISSN: 2688-2663; 2688-2663
• DOI: 10.1002/mco2.761

Neuroendocrine transdifferentiation (NEtD), also commonly referred to as lineage plasticity, emerges as an acquired resistance mechanism to molecular targeted therapies in multiple cancer types, predominately occurs in metastatic epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors and metastatic castration‐resistant prostate cancer treated with androgen receptor targeting therapies. NEtD tumors are the lethal cancer histologic subtype with unfavorable prognosis and limited treatment. A comprehensive understanding of molecular mechanism underlying targeted‐induced plasticity could greatly facilitate the development of novel therapies. In the past few years, increasingly elegant studies indicated that NEtD tumors share key the convergent genomic and phenotypic characteristics irrespective of their site of origin, but also embrace distinct change and function of molecular mechanisms. In this review, we provide a comprehensive overview of the current understanding of molecular mechanism in regulating the NEtD, including genetic alterations, DNA methylation, histone modifications, dysregulated noncoding RNA, lineage‐specific transcription factors regulation, and other proteomic alterations. We also provide the current management of targeted therapies in clinical and preclinical practice. A schematic of the cell origin of SCLC and NEPC, including de novo and NEtD.